Track Avalo Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Avalo Therapeutics Inc. Common Stock AVTX Open Avalo Therapeutics Inc. Common Stock in new tab

16.16 USD
P/E
2.30
EPS
-5.57
P/B
3.95
ROE
-72.44
Beta
0.79
Target Price
46.18 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJuly 30, 2026
P/E2.30
EPS-5.57
Book Value4.49
Price to Book3.95
Debt/Equity0.51
% Insiders1.614%
Growth
Revenue Growth-0.69%
Estimates
Forward P/E-6.18
Forward EPS-2.87
Target Mean Price46.18

DCF Valuation

Tweak assumptions to recompute fair value for Avalo Therapeutics Inc. Common Stock (AVTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Avalo Therapeutics Inc. Common Stock Logo Avalo Therapeutics Inc. Common Stock Analysis (AVTX)

United States Health Care Official Website Stock

Is Avalo Therapeutics Inc. Common Stock a good investment? Avalo Therapeutics Inc. Common Stock (AVTX) is currently trading at 16.16 USD. Market analysts have a consensus price target of 46.18 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 2.30. This relatively low multiple may signal that Avalo Therapeutics Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Avalo Therapeutics Inc. Common Stock is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is -2.87.

Investor FAQ

Does Avalo Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Avalo Therapeutics Inc. Common Stock?

Avalo Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -5.57.

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Exchange Ticker
NMS (United States) AVTX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 8, 2022 0.080000
Dec. 29, 2023 0.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion